Janux Therapeutics Inc (JANX) Stock Price, Quote & News

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 751 4493

Website: www.januxrx.com

Address:

10955 Vista Sorrento Parkway, Suite 200, San Diego, United States

Quantumup Sep. 16 at 9:06 PM

Barclays initiated coverage on $JANX at an Overweight rating and $47 and said, Janux has shown highly encouraging clinical data in late-line metastatic castration-resistant prostate cancer (mCRPC), with Progression-Free Survival (PFS) and Prostate Specific Antigen (PSA) reduction responses outperforming other late-line mCRPC options and competitive with standard of care options in earlier treatment settings. Given the performance of JANX007 to date, we view the earlier line treatment of prostate cancer with JANX007 as a logical move given its clinical efficacy to date and the economics associated with a large indication like prostate cancer. $NVS $AMGN $JNJ $AZN

0 · Reply

highnihilism Sep. 16 at 7:57 PM

IWM: Russell 2000 → $ACCO Acco Brands $DSP Viant Technology $MGPI MGP Ingredients $JANX Janux Therapeutics $FOXF Fox Factory

0 · Reply

CH_Expat Sep. 16 at 4:13 PM

$TRML 500 watchers, last post in May = bought out by Novartis. Retail knows shit in bio. I am happy with my positions in $IDYA and $JANX.

1 · Reply

highnihilism Sep. 16 at 3:11 PM

Biotech → $IRON Disc Medicine $ORIC Oric Pharmaceuticals $JANX Janux Therapeutics $NUVL Nuvalent $IMNM Immunome

0 · Reply

CH_Expat Sep. 12 at 5:28 PM

$JANX Finally opened a position here. 1100 for 24.40 USD. EV 400m is grossly undervalued, no matter how you look at it.

0 · Reply

Optionking828 Sep. 11 at 3:24 PM

$JANX same 3 year target and Janux has proved it continue to fail on ever aspect

0 · Reply

Theflash88 Sep. 10 at 7:17 PM

$JANX This: Truist Securities launched its coverage of Janux Therapeutics (NASDAQ:JANX) with a Buy recommendation and a $100 target on Wednesday, citing a catalyst-rich period for the cancer drug developer during the second half of the year.

0 · Reply

RonIsWrong Sep. 10 at 4:54 PM

$JANX ok, let's see.

1 · Reply

Quantumup Sep. 10 at 1:24 PM

Truist🏁 $JANX Buy/$100: Truist said: We initiate coverage of Janux Therapeutics ( $JANX ) with a Buy rating and $100 PT. [ $NVS $AMGN $JNJ $AZN ] Truist added: We believe the company's proprietary platforms (TRACTr and TRACIr) have the potential to overcome historical limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. Lead asset JANX007 has best-in-class potential in prostate cancer, and with multiple readouts across 2025, we see a catalyst rich year ahead. Where many peers have stumbled, Janux's masking technology offers a differentiated path to both efficacy and safety. With key data updates expected in the back half of 2025, we anticipate meaningful upside for investors.

0 · Reply

JarvisFlow Sep. 10 at 1:15 PM

Truist Securities has updated their rating for Janux Therapeutics ( $JANX ) to Buy with a price target of 100.

0 · Reply

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 5, 2025, 4:05 PM EDT - 6 weeks ago

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

Jul 31, 2025, 12:01 AM EDT - 6 weeks ago

Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash

Jul 24, 2025, 4:05 PM EDT - 7 weeks ago

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

Jul 17, 2025, 4:30 PM EDT - 2 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

May 15, 2025, 8:00 AM EDT - 4 months ago

Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer

May 8, 2025, 4:01 PM EDT - 4 months ago

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

May 5, 2025, 8:30 AM EDT - 4 months ago

Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates

Apr 5, 2025, 8:14 AM EDT - 5 months ago

Janux Therapeutics: Buying For The Promising Pipeline, Holding For The Buyout

Feb 27, 2025, 4:01 PM EST - 7 months ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Jan 24, 2025, 4:01 PM EST - 8 months ago

Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Jan 8, 2025, 9:00 AM EST - 8 months ago

Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data

Jan 2, 2025, 11:46 PM EST - 9 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR

Dec 6, 2024, 7:43 PM EST - 10 months ago

Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million

Dec 4, 2024, 11:12 PM EST - 10 months ago

Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Dec 3, 2024, 4:01 PM EST - 10 months ago

Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 10:49 AM EST - 10 months ago

Janux Therapeutics' Prostate Cancer Trial Data Exceeds Investor Expectations: Analyst

Dec 3, 2024, 10:39 AM EST - 10 months ago

Janux Therapeutics Stock Soars 70% on Prostate Cancer Drug Trial Results

Dec 2, 2024, 4:30 PM EST - 10 months ago

Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC

Nov 25, 2024, 9:00 AM EST - 10 months ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies

Nov 19, 2024, 1:23 AM EST - 10 months ago

Janux Therapeutics: Believable Theory, Strong Early Data, Needs Confirmation

Nov 6, 2024, 4:01 PM EST - 11 months ago

Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors

Jun 26, 2024, 8:32 AM EDT - 1 year ago

Janux Therapeutics: Promising T-Cell Engager Platform In Cancer Therapy

May 7, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 2, 2024, 2:10 AM EDT - 1 year ago

VKTX, JANX and these biotech stocks are surging in 2024

ARQT VKTX AMLX MCRB RAPT RVNC

Mar 20, 2024, 1:44 PM EDT - 1 year ago

Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst - Janux Therapeutics (NASDAQ:JANX)

Mar 8, 2024, 4:01 PM EST - 1 year ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 29, 2024, 1:22 AM EST - 1 year ago

Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Feb 27, 2024, 5:15 PM EST - 1 year ago

Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024

Feb 27, 2024, 5:00 PM EST - 1 year ago

Janux Therapeutics Announces Proposed Public Offering of Common Stock

Feb 27, 2024, 8:38 AM EST - 1 year ago

Janux Therapeutics surges as trial data for prostate cancer therapy shows promise

Feb 26, 2024, 4:05 PM EST - 1 year ago

Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors

Feb 20, 2024, 8:00 AM EST - 1 year ago

Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008

Jan 8, 2024, 9:00 AM EST - 1 year ago

Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer

Nov 7, 2023, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Jul 17, 2023, 8:45 AM EDT - 2 years ago

Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Janux Therapeutics Announces Positive Interim Clinical Data from Phase 1a Dose Escalation for PSMA-TRACTr JANX007 and an Update on Pipeline Programs

Jun 5, 2023, 4:35 PM EDT - 2 years ago

Janux Therapeutics Appoints Zachariah McIver, D.O., Ph.D., Vice President, Clinical Development

May 9, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Apr 24, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences

Apr 20, 2023, 4:01 PM EDT - 2 years ago

Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors

Mar 10, 2023, 4:01 PM EST - 2 years ago

Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Feb 14, 2023, 12:00 PM EST - 2 years ago

Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference

Dec 27, 2022, 9:00 AM EST - 2 years ago

Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors

Nov 22, 2022, 6:00 AM EST - 3 years ago

Janux Therapeutics to Present at Upcoming Investor Conferences in November

Quantumup Sep. 16 at 9:06 PM

0 · Reply

highnihilism Sep. 16 at 7:57 PM

IWM: Russell 2000 → $ACCO Acco Brands $DSP Viant Technology $MGPI MGP Ingredients $JANX Janux Therapeutics $FOXF Fox Factory

0 · Reply

CH_Expat Sep. 16 at 4:13 PM

$TRML 500 watchers, last post in May = bought out by Novartis. Retail knows shit in bio. I am happy with my positions in $IDYA and $JANX.

1 · Reply

highnihilism Sep. 16 at 3:11 PM

Biotech → $IRON Disc Medicine $ORIC Oric Pharmaceuticals $JANX Janux Therapeutics $NUVL Nuvalent $IMNM Immunome

0 · Reply

CH_Expat Sep. 12 at 5:28 PM

$JANX Finally opened a position here. 1100 for 24.40 USD. EV 400m is grossly undervalued, no matter how you look at it.

0 · Reply

Optionking828 Sep. 11 at 3:24 PM

$JANX same 3 year target and Janux has proved it continue to fail on ever aspect

0 · Reply

Theflash88 Sep. 10 at 7:17 PM

0 · Reply

RonIsWrong Sep. 10 at 4:54 PM

$JANX ok, let's see.

1 · Reply

Quantumup Sep. 10 at 1:24 PM

0 · Reply

JarvisFlow Sep. 10 at 1:15 PM

Truist Securities has updated their rating for Janux Therapeutics ( $JANX ) to Buy with a price target of 100.

0 · Reply

Quantumup Sep. 10 at 12:13 PM

Stifel resumed coverage of $JANX at a Buy rating and a $45 price target. Stifel said:

0 · Reply

CH_Expat Sep. 9 at 3:09 PM

$JANX @Hottehueh @WSRX @CDMO @RonIsWrong - this one looks interesting. 1b cash, nobody gives a flying .... no watchers, basically at 52-week low.

1 · Reply

CH_Expat Sep. 9 at 10:41 AM

$JANX Interested here.

0 · Reply

Quantumup Sep. 4 at 1:14 PM

Guggenheim🏁 $JANX Buy/$72. $NVS $AMGN $JNJ $AZN BNTX MRK BMY Guggenheim said in its initiation report:

0 · Reply

NVDAMillionaire Sep. 4 at 9:22 AM

$JANX Brilliant piece that captures JANX's situation perfectly. So if you want to update your understanding of JANX or get to know JANX better, this is essential reading. https://beyondspx.com/quote/JANX/janux-therapeutics-unlocking-tumor-activated-immunotherapy-with-promising-early-data-nasdaq-janx#analysis

0 · Reply

ZUffisift Sep. 2 at 7:32 PM

$JANX xbi up 3.7 % and this turd is barely green. WTF is going on

0 · Reply

marti837 Aug. 31 at 6:42 PM

$JANX

0 · Reply

VegaVoyage Aug. 27 at 10:16 AM

$JANX volume picking up, potential early sign of a breakout.

0 · Reply

theBigDollarski Aug. 26 at 4:42 PM

$JANX just started a position ....looks pretty cheap compared to other prices others bought in at earlier in the year.

1 · Reply

Optionking828 Aug. 24 at 9:22 PM

$JANX

1 · Reply

Theflash88 Aug. 21 at 5:27 PM

$JANX Piper Sandler August 19th. $42 P.T. Janux Therapeutics (NASDAQ:JANX) rated Overweight with a $42 price target: "Despite the strong reception to JANX007 clinical data in mCRPC presented in December 2024, investor enthusiasm has tapered in 2025 due to emerging competitor readouts and the company’s announcement that dose escalation for JANX007 is now complete." In 2024, Janux said the early stage data showed “substantial” activity with JANX007 in fifth-line mCRPC patients and provided “compelling support” for the doses chosen by the company for expansion trials with second and third-line pre-Pluvicto patients.

0 · Reply

ZUffisift Aug. 21 at 3:47 PM

$JANX constant selling pressure every day .. 300 puts 22.5 traded yesterday sep .. hope we don’t crater on surprise negative news

1 · Reply

Market Cap	1.45B
Revenue (ttm)	10.59M
Net Income (ttm)	-68.99M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-651.46%
Debt to Equity Ratio	0.00

Volume	570,700
Avg Vol	784,718
Day's Range	N/A - N/A
Shares Out	60.09M
Stochastic %K	31%
Beta	2.84
Analysts	Strong Sell
Price Target	$80.47